ATRS News and Press, Antares Pharma Inc. From 01/11/21

EWING, N.J., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced guidance for full-year 2021 and expects revenue to be in a range of $175 to $200 million, which assumes no significant disru...

Low-cost stocks typically trade at depressed levels for a reason. In many cases, such prices indicate deep financial troubles for a company. Nonetheless, investors should remember that some now-prominent stocks such as Advanced Micro Devices or NIO were once penny stocks . So no...

EWING, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer has participated in a fireside chat presentation and will host i...

EWING, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executive Officer is scheduled to present at the Jefferies Virtual London Healthca...

Image source: The Motley Fool. Antares Pharma Inc (NASDAQ: ATRS) Q3 2020 Earnings Call Nov 5, 2020 , 8:30 a.m. ET Operator Continue reading For further details see: Antares Pharma Inc (ATRS) Q3 2020 Earnings Call Transcript

Antares Pharma, Inc. (ATRS) Q3 2020 Earnings Conference Call November 5, 2020 8:30 a.m. ET Company Participants Tram Bui - VP, Corporate Communications and IR Bob Apple - President and CEO Fred Powell - EVP and CFO Pat Shea - SVP of Commercial Conference Call Participants Anthony Petrone - Je...

The following slide deck was published by Antares Pharma, Inc. in conjunction with their 2020 Q3 earnings call. For further details see: Antares Pharma, Inc. 2020 Q3 - Results - Earnings Call Presentation

Third Quarter 2020 Revenue Increase s 17 % Year-Over-Year to $ 40. 0 Millio n Third Quarter 2020 Net Income of $ 5. 0 Million , or EPS of $0.0 3 EWING, N.J., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Ant...

EWING, N.J., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced it will release its third quarter 2020 financial and operating results on Thursday, November 5, 2020, before the market open...

Since my last article in July, Antares has rallied over 20%, finally getting back to the lower end of where it was trading pre-COVID-19. This rally presumably has to do with the company returning to solid growth in Q2 and reporting a quarterly profit. Additionally, management made...